Clinical Trial Update: A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update shows Novo Nordisk is testing different doses of NNC0519-0130 to reduce kidney damage in people with chronic kidney disease, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• NNC0519-0130

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Chronic Kidney Disease | Phase 2 | Status: RECRUITING